# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...
Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...
Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...
Barclays analyst Gena Wang initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Overweight rating and announces Pri...
Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price t...
The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering...